EGFR and Ewing sarcoma: Although it is still too early to draw conclusions, interim reports indicate that the therapy has promise as 23% of the trial subjects expressed EGFR on IHC, and over 60% of these EGFR-positive tumors were sarcomas, including osteosarcoma, Ewing’s sarcoma, rhabdomyosarcoma, and synovial sarcoma patients.